Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
| Autor: | Kensuke Usuki, Shoichi Ohwada, Taiga Takagi, Toru Sakura, Takeshi Takahashi, Hitoshi Ohno, Kosei Matsue, Sakura Sakajiri, Masato Murakami, Ryota Imanaka |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Phases of clinical research Gastroenterology QT interval 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Japan hemic and lymphatic diseases Internal medicine Clinical endpoint Humans Medicine Benzothiazoles Adverse effect Protein Kinase Inhibitors Aged Quizartinib Salvage Therapy business.industry Phenylurea Compounds Remission Induction Myeloid leukemia Hematology Middle Aged medicine.disease Discontinuation Leukemia Myeloid Acute Treatment Outcome fms-Like Tyrosine Kinase 3 chemistry 030220 oncology & carcinogenesis Mutation Female business Febrile neutropenia 030215 immunology |
| Zdroj: | International Journal of Hematology. 110:665-674 |
| ISSN: | 1865-3774 0925-5710 |
| Popis: | FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations in patients with acute myeloid leukemia (AML) are associated with early relapse and poor survival. This multicenter, single-arm, two-stage phase 2 study (NCT02984995) was conducted to evaluate the efficacy and safety of quizartinib hydrochloride (initial dose 20/30 mg/day), an oral, highly potent, selective FLT3 inhibitor in Japanese patients (median age 65 years) with FLT3-ITD positive relapsed/refractory (R/R) AML. The composite complete remission (CRc) rate (primary endpoint) was 53.8% (90% confidence interval 36.2–70.8%) for evaluable patients in the efficacy analysis set. The median duration of CRc and overall survival was 16.1 weeks and 34.1 weeks, respectively. The most frequent treatment-emergent adverse events (TEAEs) were febrile neutropenia (43.2%), platelet count decreased (37.8%), and QT prolonged (35.1%). Two (5.4%) patients experienced TEAEs associated with treatment discontinuation. All serious TEAEs (45.9%), except febrile neutropenia (16.2%), were reported in ≤ 2 patients. The incidence of QTcF 451–480 ms and 481–500 ms was 37.8% and 2.7%, respectively. No QTcF > 500 ms, events of torsade de pointes or arrhythmia with clinical symptoms were reported. Quizartinib monotherapy was well tolerated and resulted in clinically meaningful reductions in blast count in Japanese patients with FLT3-ITD R/R AML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink